# Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

> **NCT04939428** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 2441 (actual)

## Conditions studied

- Coronavirus Disease (COVID-19)

## Interventions

- **DRUG:** Molnupiravir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04939428
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-11
- **Primary completion:** 2022-11-16
- **Final completion:** 2022-11-16
- **Target enrollment:** 2441 (ACTUAL)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04939428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04939428, "Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04939428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*